There is increasing interest in prevention of pertussis in adults by vaccination, but little is
known about the duration of the antibody response to pertussis, diphtheria or tetanus in …

Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive
combined reduced-antigen-content diphtheria–tetanus and acellular pertussis vaccine …

Three hundred and nineteen adolescents aged 10–12 years who had been previously
vaccinated with five doses of acellular pertussis-containing vaccines received single doses …

Background Over the last decades, pertussis showed periodic increases in its incidence
among adults, despite being a vaccine-preventable disease. Methods This phase III …

Persistence of antibodies after a single dose of Tdap vaccine (tetanus, diphtheria, and 5-
component acellular pertussis vaccine) was evaluated in a follow-up study of adolescents …

Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

A single blinded randomized controlled trial to compare the reactogenicity and
immunogenicity of adult formulated dTpa and monovalent pa vaccines with a licensed Td …

The duration of protection after vaccination with reduced antigen content diphtheria, tetanus
and acellular pertussis vaccines (Tdap) is not known. Long-term post-vaccination …

The aim of this assessor-blinded trial was to compare the immunogenicity and reactogenicity
of a candidate diphtheria, tetanus toxoids and acellular pertussis vaccine with reduced …